HomeAbout

TL;DR CNBC


Novavax stock jumps after company settles dispute over canceled Covid vaccine purchase - TL;DR CNBC

Novavax stock jumps after company settles dispute over canceled Covid vaccine purchase

Publishing timestamp: 2024-02-22 11:14:13


Summary

Novavax settles arbitration dispute with Gavi over canceled Covid vaccine purchase agreement, potentially paying up to $475 million. Settlement eliminates uncertainty around Novavax's future and allows Gavi to order more shots over the next five years. Novavax's business outlook could improve as a result of the settlement.


Sentiment: NEUTRAL

Tickers: NVAX

Keywords: biotech and pharmaceuticalshealth care industrybusiness newsbiotechnologybreaking newspharmaceuticalsnovavax incbusiness

Source: https://www.cnbc.com/2024/02/22/novavax-to-settle-gavi-arbitration-over-canceled-covid-shot-purchase.html


Developed by Leo Phan